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Pneumococcal Vaccine Effectiveness and Its Interaction With 
Age: A UK Population Based Study in Older Adults 
Background 
A recent, large-scale trial found pneumococcal vaccination to be effective against 
pneumococcal pneumonia in older adults, yet was not powered to determine efficacy with age. 
Routinely collected data health records offer an opportunity to investigate vaccine effectiveness 
by age, and recently developed quasi-experimental methods provide a means of adjusting for 
confounding effects that commonly bias observational data. 
Objectives 
 This study sought to determine the age-specific effectiveness of the pneumococcal 
vaccination in UK adults aged 65y and older. 
Methods 
Setting 
Three annual cohorts of adult patients aged 65y and older, who were recommended 
vaccination against streptococcus pneumoniae from 2003 to 2005, were recruited from the 
data of patients from general practices registered to the Clinical Practice Research Datalink 
with linkage to Hospital Episode Statistics and the Office of National Statistics databases. 
Exposure 
Pneumococcal vaccination 
Main outcome measure 
Survival times until a composite outcome comprising hospitalisation for pneumococcal 
pneumonia and antibiotic prescribing for lower respiratory tract infections. 
Statistical analysis 
The results from three quasi-experimental methods were obtained for comparison. The 
marginal effect across each cohort was estimated from a survival analysis with inverse 
probability treatment weights. The weights were from  high-dimensional propensity scores 
based on potential confounders. Two before-and-after approaches, the prior event rate 
ratio and the pairwise methods, enabled an investigation of the age interaction, as well as 
sub-groups. 
Results 
For the 2005 cohort of patients aged over 64y, the risk of experiencing an infection with 
symptoms consistent with those of pneumococcal pneumonia was reduced by five percent 
(95% confidence interval 1% to 8%), by nine percent (2% to 16%) for the older 2004 cohort 
comprising ages over 74y, and by 11% (7% to 16%) for 2003 cohort of ages over 79y. The 
age-related pattern was repeated for key age sub-groups across all three cohorts. The 
interaction with age was modelled across all the ages in the 2005 cohort, and found to be 
significant at the 5% level, with predicted risk reductions of 4%, 12% and 15% at ages 65y, 
75y and 80y, respectively 
 
Conclusions 
 
All three methods consistently estimated an effectiveness of the pneumococcal vaccine that 
increases with age among patients aged 65y and older. The pre-adjusted bias suggests that 
the vaccination is targeted towards those most likely to benefit long-term from immunity to 
pneumococcal infection. 
 
 
 
